Balchem Corporation (BCPC) Investor Relations Documents

Balchem Corporation (BCPC) investor relations documents from the company's IR site: 10 presentations, 23 press releases; latest deck 2024-06-13. Read in-app with summaries. First-party data.

Benefits of Vitamin K2 and D3 for Heart Health: Balchem promotes its K2VITAL™ Vitamin K2 and D3 product line, highlighting a study showing a 12% increase in maximal cardiac output in athletes.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-07-31Press releaseBalchem Reports Second Quarter 2026 Financial Results
2026-07-09Press releaseBalchem to Participate in the CJS Securities 26th Annual New Ideas Summer Conference on July 9, 2026
2026-05-01Press releaseBalchem Corporation Announces Global Price Increase for Animal Nutrition and Health Products
2026-04-30Press releaseBalchem Reports First Quarter 2026 Financial Results
2026-04-30Press release1st Quarter 2026 Financial Results
2026-04-17ESG report2025 Sustainability Report
2026-04-02Press releaseNew Clinical Study Uncovers Potential K2VITAL™ Post-Exercise Neuromuscular Signaling in Older Adults
2026-03-11Press releaseBalchem to Participate in the BNP Paribas Exane Consumer Ingredients & Chemicals Conference on March 11, 2026
2026-03-10Press releaseBalchem to Participate in the JP Morgan Consumer Ingredients Forum on March 10, 2026
2026-03-09Press releaseBalchem Plant Nutrition Launches Metalosate® T.E.A.M.™ Plant Tissue Analysis Digital Platform
2026-02-20Press releaseBalchem Reports Fourth Quarter and Full Year 2025 Financial Results
2026-01-14Press releaseBalchem to Attend the CJS Securities 26th Annual New Ideas for the New Year Virtual Conference on January 14, 2026
2025-12-09Press releaseBalchem Announces Dividend
2025-11-12Press releaseBalchem to Present at Baird’s 55th Annual Global Industrial Conference on November 12, 2025
2025-09-09Press releaseBalchem to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9, 2025
2025-03-25Press releaseBalchem Corporation Announces Price Increase
2025-03-04Press releaseThe Role of Vitamins K2 MK-7 and D3 in Alleviating Long COVID Symptoms
2025-02-21Press releaseBalchem Reports Fourth Quarter and Full Year 2024 Financial Results
2025-02-03Press releaseBuild Your Inner Strength: Balchem and FC Bayern Women Forge Multi-Year Partnership with K2VITAL™
2024-12-09Press releaseBalchem Announces Dividend
2024-10-25Press releaseBalchem Reports Third Quarter 2024 Financial Results
2024-07-26Press releaseBalchem Corporation Reports Second Quarter 2024 Financial Results
2024-07-26Press releaseBalchem Announces Second Quarter 2024 Financial Results
2024-06-13Fact sheetBenefits of Vitamin K2 and D3 for Heart Health
2024-06-03Fact sheetIntroducing Optifolin+®: Balchem Unveils the Launch of Optifolin+®
2024-04-22ESG reportBalchem Releases 2023 Sustainability Report
2024-01-16PresentationTOP 2024 Evolving Trends in Health and Nutrition
2023-04-26ESG reportBalchem Releases 2022 Sustainability Report
2023-01-11PresentationBalchem Corporation Presents at the CJS Securities 23rd Annual “New Ideas for the New Year” Investor Conference on Janua
2022-09-08Fact sheetBoron Function in Tree Fruit
2022-06-30PresentationFeeding A Growing Population
2022-04-22ESG reportBalchem Releases 2021 Sustainability Report
2022-01-12PresentationBalchem Presents at the CJS Securities 22nd Annual New Ideas for the New Year Conference on January 12, 2022
2021-09-24Fact sheetChelated Minerals: The Benefit of Metalosate® Products
2021-04-26ESG reportBalchem Releases 2020 Sustainability Report
Press releaseBalchem unleashes the power of folate with Optifolin+
Earnings deck1st Quarter 2026 Earnings Presentation
ESG reportBalchem Releases 2025 Sustainability Report
ESG reportBalchem Releases 2024 Sustainability Report
Fact sheetMetalosate® Big 5™ Supporting Corn and Soybean Production

BCPC overview · BCPC earnings · BCPC financials · BCPC KPIs · BCPC ownership · BCPC peers · BCPC filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.